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Introduction 65
B7h (CD275, also known as ICOSL, B7H2, B7-RP1, GL50) belongs to the B7 family of surface 66 receptors and it binds ICOS (CD278), which belongs to the CD28 family (1) (2) (3) (4) (5) . ICOS is expressed 67 by activated T cells, whereas B7h is expressed by a wide variety of cell types, including B cells, 68 macrophages, and dendritic cells (DC) (in both species) (6-11). However, recent reports have shown that the B7h:ICOS interaction can 74 trigger bidirectional signals able to modulate also the response of the B7h-expressing cells. In 75 mouse DC, this B7h-mediated "reverse signalling" induces partial maturation with prominent 76 augmentation of IL-6 secretion (12). In human DC, it modulates cytokine secretion, promotes the 77 capacity to cross-present endocytosed antigens in class I MHC molecules, and inhibits 78 adhesiveness to EC and migration (13, 14) . B7h stimulation also inhibits the adhesiveness and 79 migration of EC and tumor cell lines in vitro and development of experimental lung metastases in 80 vivo (15,16). These effects are accompanied by decreased phosphorylation of ERK and p38 in EC; 81 decreased phosphorylation of focal adhesion kinase and down-modulation of β-Pix in EC and 82 tumor cells. Moreover, triggering of B7h potentiates signaling via several pattern recognition 83 receptors in human DC through a signaling pathway involving the adaptor protein Receptor for 84 activated C kinase 1 (RACK1) and the kinases protein kinase C (PKC) and JNK (14) . 85 The aim of our research was to extend these analyses by investigating the expression and function 86 of B7h in osteoclasts (OCs) which derive from the monocyte lineage, similarly to DC. OCs are 87 giant cells formed by the cell-cell fusion of monocyte-macrophage precursors and characterized by 88 multiple nuclei, abundant vacuoles, and lysosomes; they play a key role in bone remodelling, which 89 6 involves also osteoblasts (OBs) and osteocytes. OCs differentiate from monocytes under the 90 influence of M-CSF and receptor activator of nuclear factor-kappa B ligand (RANKL) (17) (18) (19) (20) (21) . 91
The OCs function is stimulated by the triggering of receptor activator of nuclear factor-kappa B 92 RANK expressed on the membrane of OCs by RANKL. In healthy bone, RANKL is mainly 93 expressed by OBs as a surface receptor in response to bone-resorbing factors and it is cleaved into a 94 soluble molecule by metalloproteinases (MMPs). Moreover, RANKL is also expressed by stromal 95 cells, lymphocytes, and macrophages which can support OCs function during inflammation. remodelling, after bone resorption, OBs are recruited within the resorption site and the resorption 106 lacuna is filled with bone matrix secreted by these cells; the matrix will then be mineralized by 107 precipitation of hydroxyapatite crystals (21). 108
Increased OCs activity leads to bone loss and can be detected in conditions such as osteoporosis, 109 rheumatoid arthritis (RA), and other autoimmune diseases, in which a key role has been ascribed to 110 inflammatory cytokines and adaptive immunity (24 
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Fc but not with RANKL. The mice were sacrificed 4 h after the last injection, and tibias, and 218 femurs were collected for analysis. 219
For ovariectomy (OVX)-induced osteoporosis, we used 56-day old C57BL/6 female mice and 220 groups were composed from the same littermates. Bilateral OVX was performed in mice 221
anesthetized with a mix of Zoletil® (60mg/kg) and Xilazina® (20mg/kg) i.p, as reported (35, 36) . 222
The sham-control group received the same surgical procedures except for removal of the ovaries. 223
One day after surgery, mice were treated with seven i.p. injections (1 every 4 d for 4 wk) of either 224 PBS or msICOS-msFc (400μg). They were sacrificed 4 d after the last injection and organs and 225 bones were collected for analysis. 226
Bone samples were fixed at room temperature for 2 d in 4% phosphate buffered formaldehyde pH 227 6.9, and undecalcified bones were dehydrated in ethanol before performing a three-step 228 impregnation in methylmethacrylate monomer (Merck, Darmstadt, Germany) for 3 d. Sections 229 were cut on a Leica SP 1600 Saw Microtome and mounted on polyethylene slides. 230
The cut was performed on the long axis of the bone in the femur and tibia metaphysis for trabecular 231 bone, and at the mid diaphysis for cortical bone. The sections were stained with light-green 232 (Fig. 1A) . The morphological analysis 264
showed that the cells acquired a spindle-like morphology at T14 (data not shown) and enlarged and 265 fused in multinuclear cells at T21, as expected (Fig. 1B) . Gating of the cytofluorimetric analyses on 266 the cells with the highest size and granularity showed that these cells expressed B7h at T21 267 (Fig.1C) . Moreover, expression of B7h was assessed at T21 by indirect immunofluorescence and 268 microscopy analysis. Cells were stained after fixing and permeabilization in order to stain nuclei 269 and detect both extra-and intracellular B7h, since both expressions have been detected in other cell 270 types (37,38). Results showed that B7h was expressed in both mononuclear and multinuclear cells 271 (Fig. 1C) . Finally, to confirm expression of B7h, we analyzed its mRNA by Real Time PCR and 272 the protein by western blot at T7, T14 and T21. Results confirmed that B7h expression decreased 273 during MDOCs differentiation, but it was maintained at T21, especially at the protein level (Fig.  274   1D) . 275
276

Effects of B7h triggering on OCs differentiation 277
Since B7h is expressed during the MDOCs differentiation culture, we evaluated the effect of B7h 278 triggering on differentiating MDOCs using ICOS-Fc. To assess the specificity of the ICOS effect, 279 cells were also treated with either Fc had no effect on monocyte proliferation in any culture condition (Fig. S1) . 285
Treatment of differentiating MDOCs was started at either T0 or T14 of the culture by adding the 286 ICOS reagents to the differentiating medium. The culture was continued up to T21 to perform the 287 T 0-21 and T 14-21 treatments (Fig. S1 ). 288
The results showed that the T 0-21 treatment with ICOS-Fc or ICOS-msFc powerfully inhibited 289
MDOCs differentiation. At d10 (T10), cells displayed a round shape (data not shown) and, at T21, 290 they acquired a spindle-like morphology and showed decreased the formation of multinuclear 291 TRAP positive cells (expressed as % TRAP-positive cells) ( Fig. 2A,B) . Cytofluorimetric analysis 292
showed minimal downregulation of CD14 and upregulation of Cathepsin K (Fig. 2C) . By contrast, 293 cells treated with ICOS-Fc displayed a pattern similar to that of untreated cells (Fig. 2D) (Fig. 3) . 309
The 
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Fc were similar to untreated cells (Fig. 4) . Actin staining and TRAP assay performed on these cells 318 at T21 showed data similar to those detected in the T 0-21 treatment (Fig. S2) . 319
To assess reversibility of the ICOS-Fc effect, cells were treated with the different ICOS reagents at 320 T7 washed at T14 and then incubated to T21 in the absence of the ICOS reagents (T 7-14 treatment) 321 (Fig. S1) . The results showed that the T 7-14 treatment induced a morphology, phenotype, actin 322 staining and TRAP activity converging on that displayed by untreated cells (Fig. S3) . By contrast, 323 cells that, after the T14 washing, were cultured again in the presence of the ICOS reagents (T (Fig. 6B) . 357
To confirm these data, we assessed the effect of ICOS on the osteolytic activity of MODCs on 358 dentine disks. MDOCs differentiation was induced in wells containing dentin disks in the presence 359 and absence of the ICOS reagents using T 14-21 and T 21-24 protocols. At the end of the culture, the 360 disks were stained with toluidine blue and erosion pits were visualized with a microscope and 361 quantified with a dedicated software. The results showed that the T 14-21 and T 21-24 treatments with 362 ICOS-Fc significantly decreased the erosion compared with untreated MDOCs, whereas F119S 
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Fc did not display any effect (Fig. 6C) . 364
To investigate the effect of B7h triggering at the signaling level, we treated MDOC at T21 in the 365 absence and presence of either ICOS-Fc or ICOS-msFc or ICOS-Fc. By contrast, no effect was detected on phospho-ERK, phospho-JNK, β-371 Pix, and phospho-PKC (Fig. 7) . 372 Finally, we assessed the effect of B7h triggering in vivo using two mouse models of osteoporosis. 373
Firstly, 49-day-old female C57BL/6 mice were injected i.p. daily for 3 d with RANKL (1 mg/kg) 374 alone or in combination with either an msICOS-huFc (formed by the mouse ICOS and the human 375 Fc) or F119S ICOS-Fc (100 µg/mouse). The mice were sacrificed 4 h after the last injection. 376
Histological representative images of cortical and trabecular bone stained with fucsin and light-377 green that evidenced fibrous and medullary tissues in red and mineralized bone in green are 378 reported in Fig. 8A and Fig. S4 . Morphometric measurements of mineralized bone tissue in the 379 cortical and trabecular bone showed a marked bone loss in the RANKL-injected mice compared to 380 control mice (Fig. 8B) , as expected (34). This bone loss was significantly inhibited by co-treatment 381 of mice with RANKL plus msICOS-huFc but not with RANKL plus In the sham mice, no bone loss was detected and treatment with ICOS-Fc did not show any effect 390 (Fig. 9A-B) . To evaluate whether the ICOS-Fc effect was ascribable to decreased OCs activity, we 391 evaluated expression of DC-STAMP and NFATc1 in the mRNA extracted from these bones by 392
Real Time PCR. Results, showed that the treatment with ICOS-Fc significantly decreased the levels 393 of DC-STAMP and NFATc1 compared to the controls. In the sham mice, levels of DC-STAMP and 394
NFATc were significantly lower than in control OVX mice and were not modulated by treatment 395 with ICOS-F (Fig. 9C) . 396 397 Discussion 398
Bone remodeling is a complex process managed by OBs and OCs, and the immune system is 399 involved in regulating the function of these cells through the activity of cytokines and surface 400
receptors. This paper has described a novel pathway involved in the lymphocyte/bone cell 401 interactions by showing that the binding of ICOS, expressed by activated T cells, to its ligand B7h, 402 expressed by OCs, inhibits OCs maturation and function. These effects were detected using ICOS-403 Fc and they were specific, since they were not displayed by 
